Yue Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yue Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Jicheng Han
Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117
2 shared publicationsNingyi Jin
Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117
2 shared publicationsShanzhi Li
Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117
2 shared publicationsXia Yang
Medical College, Yanbian University , Yanji 133002
2 shared publicationsYaru Li
Medical College, Yanbian University , Yanji 133002
2 shared publications- Yilong Zhu
Key Laboratory of Jilin Province for Traditional Chinese Medicine Prevention and Treatment of Infectious Diseases, College of Integrative Medicine, Changchun University of Chinese Medicine, Changchun, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 6690588
Identification and Functional Characterization of a Novel PRPS1 Variant in X‐Linked Nonsyndromic Hearing Loss: Insights From Zebrafish and Cellular Models
Purpose: The study was aimed at identifying the pathogenic gene responsible for X‐linked nonsyndromic hearing loss (NSHL) in a five‐generation Chinese family and at elucidating the gene’s function both in vivo using a zebrafish model and in vitro using PRPS1 knockdown HEI‐OC1 cells.Methods: Exome sequencing (ES) and Sanger sequencing were used to identify the pathogenic variants. A transgenic zebrafish model overexpressing the novel PRPS1 variant (c.494G>A: p.Cys165Tyr) was constructed, and PRPS1 was knocked down in HEI‐OC1 cells using siRNA to explore the underlying mechanisms. Hair cell development and behavior were assessed in zebrafish, and mitochondrial function and cell viability were analyzed in HEI‐OC1 cells.Results: A novel missense variant (c.494G>A: p.Cys165Tyr) in the PRPS1 gene was identified as the pathogenic variant causing progressive X‐linked deafness‐1 (DFNX1). The variant led to hair cell death in zebrafish, with disrupted swimming behavior. In HEI‐OC1 cells, PRPS1 knockdown resulted in downregulation of the nicotinamide adenine dinucleotide (NAD+)/sirtuin 3 (SIRT3)/superoxide dismutase 2 (SOD2) pathway, increased reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and apoptosis, which were partially rescued by pretreatment with nicotinamide mononucleotide (NMN), a precursor of NAD+.Conclusion: The study reports a novel PRPS1 variant contributing to the variant spectrum of PRPS1 and highlights the role of PRPS1 deficiency in increasing oxidative stress‐induced hair cell apoptosis via the NAD+/SIRT3/SOD2 pathway. These findings provide new insights into the molecular mechanisms of PRPS1‐related hearing loss and potential therapeutic targets.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 6690588
Open AccessIdentification and Functional Characterization of a Novel PRPS1 Variant in X‐Linked Nonsyndromic Hearing Loss: Insights From Zebrafish and Cellular Models
Purpose: The study was aimed at identifying the pathogenic gene responsible for X‐linked nonsyndromic hearing loss (NSHL) in a five‐generation Chinese family and at elucidating the gene’s function both in vivo using a zebrafish model and in vitro using PRPS1 knockdown HEI‐OC1 cells.Methods: Exome sequencing (ES) and Sanger sequencing were used to identify the pathogenic variants. A transgenic zebrafish model overexpressing the novel PRPS1 variant (c.494G>A: p.Cys165Tyr) was constructed, and PRPS1 was knocked down in HEI‐OC1 cells using siRNA to explore the underlying mechanisms. Hair cell development and behavior were assessed in zebrafish, and mitochondrial function and cell viability were analyzed in HEI‐OC1 cells.Results: A novel missense variant (c.494G>A: p.Cys165Tyr) in the PRPS1 gene was identified as the pathogenic variant causing progressive X‐linked deafness‐1 (DFNX1). The variant led to hair cell death in zebrafish, with disrupted swimming behavior. In HEI‐OC1 cells, PRPS1 knockdown resulted in downregulation of the nicotinamide adenine dinucleotide (NAD+)/sirtuin 3 (SIRT3)/superoxide dismutase 2 (SOD2) pathway, increased reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and apoptosis, which were partially rescued by pretreatment with nicotinamide mononucleotide (NMN), a precursor of NAD+.Conclusion: The study reports a novel PRPS1 variant contributing to the variant spectrum of PRPS1 and highlights the role of PRPS1 deficiency in increasing oxidative stress‐induced hair cell apoptosis via the NAD+/SIRT3/SOD2 pathway. These findings provide new insights into the molecular mechanisms of PRPS1‐related hearing loss and potential therapeutic targets.
- Open Access
- 25 November 2023
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (5) , 545-558
Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice
Objectives: Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated. Methods: The protective effects were evaluated by the disease activity index, colonic length, hematoxylin–eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis. Key findings: The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of jak1/2, p-jak1/2, stat1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia). Conclusions: Peimisine can ameliorate colitis by inhibiting Jak–Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.
- 25 November 2023
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (5) , 545-558
Open AccessPeimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice
Objectives: Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated. Methods: The protective effects were evaluated by the disease activity index, colonic length, hematoxylin–eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis. Key findings: The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of jak1/2, p-jak1/2, stat1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia). Conclusions: Peimisine can ameliorate colitis by inhibiting Jak–Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.
- Open Access
- 10 February 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 102
Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway
- 10 February 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 102
Open AccessBetulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway